TACS 2 TdT_Core Kit
- Known as:
- TACS 2 TdT_Core Kit
- Catalog number:
- 4810-30-CK
- Product Quantity:
- 30 Samples
- Category:
- -
- Supplier:
- Trevigen
- Gene target:
- TACS 2 TdT_Core Kit
Related genes to: TACS 2 TdT_Core Kit
- Gene:
- EPCAM NIH gene
- Name:
- epithelial cell adhesion molecule
- Previous symbol:
- M4S1, MIC18, TACSTD1
- Synonyms:
- Ly74, TROP1, GA733-2, EGP34, EGP40, EGP-2, KSA, CD326, Ep-CAM, HEA125, KS1/4, MK-1, MH99, MOC31, 323/A3, 17-1A, TACST-1, CO-17A, ESA
- Chromosome:
- 2p21
- Locus Type:
- gene with protein product
- Date approved:
- 1995-10-02
- Date modifiied:
- 2019-04-23
Related products to: TACS 2 TdT_Core Kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit(1-Kit) 14,15-EET_DHET Hypertension ELISA Kit Related articles to: TACS 2 TdT_Core Kit
- Congenital tufting enteropathy (CTE), or autosomal recessive congenital diarrhea type 5 (DIAR5), is a rare intestinal epithelial disorder characterized by severe neonatal-onset watery diarrhea, failure to thrive, and intestinal failure. Most cases are caused by biallelic EPCAM variants. A 53-day-old female infant presented with severe watery diarrhea and failure to thrive from the first days of life. She was born at term with a birth weight of 3.4 kg and had 10-20 watery stools daily. At admission, she was dehydrated, dystrophic, and below the third weight percentile. Diarrhea persisted despite an amino acid-based formula and cessation of enteral feeding. Duodenal biopsy showed disturbed villous-crypt architecture, variable lamina propria inflammation, absence of intraepithelial lymphocytosis, epithelial tufts, and regenerative epithelial changes, supporting CTE. Whole-exome sequencing identified compound heterozygous EPCAM variants: a maternally inherited likely pathogenic frameshift variant, c.687_688del, p.(Lys230Asnfs*23), and a paternally inherited missense variant, c.757G>A, p.(Asp253Asn), classified as a variant of uncertain significance. TPN was initiated for intestinal failure. Follow-up was complicated by catheter-related sepsis, cholelithiasis, and recurrent pancreatitis requiring laparoscopic cholecystectomy. She subsequently tolerated limited enteral feeding but did not achieve enteral autonomy and remained dependent on TPN, while maintaining normal growth with nutritional support. CTE should be considered in infants with severe neonatal-onset diarrhea. Histopathology combined with genetic testing is essential for diagnosis. Long-term TPN and multidisciplinary management are required. - Source: PubMed
Publication date: 2026/09/12
Rogalidou MariaDimakou KonstantinaStefanaki KalliopiPatereli AmaliaPapadopoulou Alexandra - Accurate detection of lymph node (LN) metastases is critical for prognosis and surgical decision-making in head and neck squamous cell carcinoma (HNSCC) and other epithelial cancers. Standard histopathology examines only a small fraction of LN tissue, limiting sensitivity for micrometastases and isolated tumour cells. Scalable approaches are needed to improve staging accuracy and reduce overtreatment. We adapted the FDA-approved CELLSEARCH System, originally developed for circulating tumour cell detection, for use on dissociated 50 μm formalin-fixed paraffin-embedded (FFPE) LN sections. Tumour cells were enriched via EpCAM-based immunomagnetic capture, stained with cytokeratin (CK)/DAPI and quantified using the ACCEPT (Automated CTC Classification, Enumeration and Phenotyping Technology) image analysis tool. Specificity and reproducibility were tested in 50 metastasis-positive and 50 metastasis-free LNs from patients with HNSCC. Enriched cells underwent single-cell and pooled whole-genome amplification (WGA), quality-controlled by a genomic integrity index and profiled for copy number alterations (CNA) by low-pass whole-genome sequencing. Tumour cells were detected in 100% of LN metastases (range: 37-12,479), with counts strongly correlating with histological tumour area (p < 0.0001). Rare background events in control LNs were excluded by manual CELLSEARCH review. Based on their frequency, a threshold of > 12 cells was defined to classify samples as positive, yielding an assay specificity and sensitivity of 100%. Reproducibility across adjacent sections was high. Despite FFPE preservation, WGA succeeded in 27% of single cells and > 75% of pooled fractions. CNA profiling yielded 50 high-quality tumour genomes, revealing typical HNSCC alterations and marked inter-/intra-patient heterogeneity. This adapted CELLSEARCH workflow enables sensitive detection and genomic profiling of tumour cells from FFPE LN tissue. Demonstrated in HNSCC as a proof of concept, the approach is broadly applicable to epithelial cancers where LN staging is prognostically decisive. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. - Source: PubMed
Publication date: 2026/09/21
Bergmann TristanHölbling MarianneSudarsanam MonicaDriemel ChristianeDaniels Maximilian ESwierz JoannaJaschinski SandraSeidl MaximilianKübler Norbert RKnoefel Wolfram TNeves Rui PlSproll Karl CStoecklein Nikolas H - Epithelial Cell Adhesion Molecule positive (EpCAM) extracellular vesicles (EVs) can promote cancer progression and metastasis. Thus, it is necessary to develop targeted strategies to disable EpCAM EVs. - Source: PubMed
Publication date: 2026/08/05
Su NingZhang WenjiaTang JiayuLiu WeiZhao JiandongGao MingxiaZhang Xiangmin - EpCAM is overexpressed in solid tumors and is a promising pan-tumor imaging target, yet clinically applicable PET tracers are limited. We developed and evaluated a novel EpCAM-targeted tracer, Ga-DOTA-EP-1. The peptide sequence EP-1 (YEVHTYYLD) was previously identified as an EpCAM-binding ligand via high-throughput bi-functional microarray screening. Based on this scaffold, we performed chemical modification by conjugating a DOTA chelator via an Acp linker to enable Ga radiolabeling for PET imaging. After labeling, stability, lipophilicity, protein binding, and specificity were evaluated in EpCAM-positive and -negative cell lines. In vivo PET imaging, biodistribution, immunohistochemistry, and toxicity were performed in tumor-bearing mice, followed by a preliminary clinical study. Ga-DOTA-EP-1 exhibited high radiochemical purity and excellent stability. Cellular uptake was significantly higher in EpCAM-positive cells (P < 0.05), with high binding affinity confirmed by blocking and IC assays. PET imaging showed markedly higher uptake in EpCAM-positive xenografts, significantly reduced by blocking. Preliminary clinical imaging demonstrated favorable safety and clear visualization of hepatic metastases. These findings suggest that Ga-DOTA-EP-1 has the potential to serve as an EpCAM-targeted PET tracer with favorable specificity and a promising safety profile for further clinical evaluation. - Source: PubMed
Publication date: 2026/09/18
Tang ShijieLiu YanggangHui ShiboLiu MiaoZhang YangAi YihengChen YueLi XiangQiu Lin - Lymph node (LN) metastasis is a major determinant of prognosis in gastric cancer, yet the immune microenvironment of metastatic versus non-metastatic nodes remains incompletely defined. Spatial resolution of tumor-immune interactions may clarify mechanisms of immune escape associated with nodal progression. We performed compartment-resolved spatial transcriptomic profiling to characterize immune gene expression in gastric cancer LNs. Forty-seven formalin-fixed paraffin-embedded LNs from 13 patients with T2-T4, M0 gastric adenocarcinoma (N1-2: n = 7; N3: n = 6) were analyzed using the NanoString GeoMx Digital Spatial Profiler and an 84-gene immune pathways panel. Twenty-nine non-metastatic and 18 metastatic LNs were profiled. Regions of interest were segmented into tumor and immune compartments, yielding 65 spatially defined compartments. Differential expression was assessed across three comparisons: metastatic versus non-metastatic LNs; metastatic LNs from N1-2 versus N3 patients; and non-metastatic LNs from N1-2 versus N3 patients. Within the immune compartments, non-metastatic LNs showed higher expression of T-cell activation and checkpoint genes (CD3E, CD27, PDCD1, CTLA4), consistent with preserved immune surveillance. Metastatic LNs were enriched for WNT signaling and adhesion-related genes (CTNNB1, ITGAV) and epithelial markers (EPCAM), indicating tumor-driven immune remodeling. N3 metastatic LNs demonstrated increased ICOSLG, IL6, and IFNGR1 expression, suggesting chronic inflammatory activation and immune dysfunction. Notably, non-metastatic LNs from N3 patients upregulated antigen-presentation genes (CD74, HLA-DRB), consistent with early immune conditioning. No significant differences emerged in tumor compartments or pseudo-bulk analyses. Spatial transcriptomic profiling reveals nodal burden-associated immune remodeling, and identifies candidate biomarkers and therapeutic targets for precision immunotherapy in gastric cancer. - Source: PubMed
Publication date: 2026/09/17
Suwatthanarak ThanawatNampoolsuksan ChawisaTanjak PariyadaThanormjit KullanistAcharayothin OnchiraChaiboonchoe AmphunSuwatthanarak TharathornPithukpakorn ManopChalermwai Wipapat VickiSwangsri JirawatMethasate AsadaChinswangwatanakul VitoonParakonthun Thammawat